{"disease":{"id":"breast-surgery","name":"breast surgery"},"drugs":{"marketed":[{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, and/or prior surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, and/or prior hormone therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, and/or prior targeted therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, and/or prior immunotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, and/or prior chemotherapy with a taxane","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, and/or prior chemotherapy with a platinum agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, and/or prior chemotherapy with a microtubule inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, and/or prior chemotherapy with a PARP inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, and/or prior chemotherapy with a CDK4/6 inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, and/or prior chemotherapy with a mTOR inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, and/or prior chemotherapy with a HER2-targeted therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, and/or prior chemotherapy with a PIK3CA-targeted therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, and/or prior chemotherapy with a hormone receptor antagonist","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, and/or prior chemotherapy with a hormone receptor agonist","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, and/or prior chemotherapy with a selective estrogen receptor degrader","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, prior chemotherapy with a selective estrogen receptor degrader, and/or prior chemotherapy with a selective estrogen receptor modulator","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, prior chemotherapy with a selective estrogen receptor degrader, prior chemotherapy with a selective estrogen receptor modulator, and/or prior chemotherapy with a cyclin-dependent kinase 4/6 inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, prior chemotherapy with a selective estrogen receptor degrader, prior chemotherapy with a selective estrogen receptor modulator, prior chemotherapy with a cyclin-dependent kinase 4/6 inhibitor, and/or prior chemotherapy with a CDK4/6 inhibitor and/or a PIK3CA inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":18,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07059104","title":"Implant-based Breast Reconstruction in Post-bariatric Women - a Registry-based National Study","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT04030845","title":"Patient Report Outcome-Reconstruction and Oncoplastic Cohort","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05054777","title":"Patient Report Outcome and Oncological Safety -Oncoplastic and Conventional BCS Cohort","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Shandong Cancer Hospital and Institute","has_results":false},{"nct_id":"NCT06888388","title":"Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":4700,"lead_sponsor_name":"Sir Mortimer B. Davis - Jewish General Hospital","has_results":false},{"nct_id":"NCT06429644","title":"Long-term Oncologic Outcome of Breast-conserving Surgery in Breast Cancer Patients With BRCA1/2 Mutations","phase":"","overall_status":"COMPLETED","enrollment_count":4010,"lead_sponsor_name":"Hanyang University Seoul Hospital","has_results":false},{"nct_id":"NCT06761196","title":"Quality of Life After Breast Cancer Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Centre Hospitalier de Colmar","has_results":false},{"nct_id":"NCT06869629","title":"Omission of Axillary Lymph Node Dissection in Case of Tumor Spread to Lymph Nodes in the Armpit in Breast Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1380,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT07185568","title":"IntraOperative UltraSound Guided vs Wire Guided vs Magnetic Seed Guided Breast-Conserving Surgery for Non-palpable Tumors","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1302,"lead_sponsor_name":"Istituto Oncologico Veneto IRCCS","has_results":false},{"nct_id":"NCT06728527","title":"PARTial BREast RECONstruction With Chest Wall Perforator Flap","phase":"","overall_status":"RECRUITING","enrollment_count":1001,"lead_sponsor_name":"Cambridge University Hospitals NHS Foundation Trust","has_results":false},{"nct_id":"NCT06425874","title":"The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT07283120","title":"The Impact of Breast Surgery on Patients' Quality of Life","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT02056886","title":"Medico-economic Study of Three Strategies of Sentinel Lymph Node Analysis in Operable Breast Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":858,"lead_sponsor_name":"Institut Cancerologie de l'Ouest","has_results":false},{"nct_id":"NCT06906601","title":"Preoperative Magnetic Tracking in Breast Surgery in France: French Medical-economic Study.","phase":"","overall_status":"RECRUITING","enrollment_count":772,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT04108117","title":"Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction","phase":"","overall_status":"COMPLETED","enrollment_count":659,"lead_sponsor_name":"Severance Hospital","has_results":false},{"nct_id":"NCT04689529","title":"Unnecessary Mastectomy Due to False Size Prediction by Preoperative Imaging Studies in Breast Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":360,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT04456855","title":"Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":358,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05060068","title":"Effect of Intravenous S-ketamine on Opioid Consumption","phase":"NA","overall_status":"COMPLETED","enrollment_count":345,"lead_sponsor_name":"The Second Hospital of Anhui Medical University","has_results":false},{"nct_id":"NCT03604666","title":"Follow-up of Elderly Patients in Ambulatory Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":320,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04817813","title":"Long-term Outcomes After Breast Cancer Liver Metastasis Surgery: an European, Retrospective, Snapshot Study","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Hospital Miguel Servet","has_results":false},{"nct_id":"NCT04626986","title":"Comparison of Microwave Ablation With Breast Conserving Surgery for Breast Tumor","phase":"NA","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT03878342","title":"Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":295,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT04827030","title":"ER-One: A Double-blind Trial of Erector Spinae Block (ESP) Versus Paravertebral Block (PVB) Before Breast Cancer Surgery","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":292,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT07230535","title":"Evaluation of Wellbeing and Patient Reported Outcomes After Open vs Robotic Mastectomy With DIEP Reconstruction","phase":"NA","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Beaumont Hospital","has_results":false},{"nct_id":"NCT06906237","title":"Scarless Advanced Breast Extended Oncoplasty: The ScarABEO Study","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Istituto Oncologico Veneto IRCCS","has_results":false},{"nct_id":"NCT06712524","title":"Effect of Different Surgical Approaches of Granulomatous Mastitis","phase":"NA","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Hubei Cancer Hospital","has_results":false},{"nct_id":"NCT05782686","title":"Impact of Systematic Shaving on Margins","phase":"NA","overall_status":"RECRUITING","enrollment_count":234,"lead_sponsor_name":"Hospital Universitari de Bellvitge","has_results":false},{"nct_id":"NCT07458646","title":"Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Perioperative Negative Emotions in Breast Cancer Surgery Patients","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":232,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT04487561","title":"Hemopatch Versus Axillary Drainage After Axillary Lymphadenectomy","phase":"NA","overall_status":"COMPLETED","enrollment_count":228,"lead_sponsor_name":"Fundación para la Investigación del Hospital Clínico de Valencia","has_results":false},{"nct_id":"NCT03963427","title":"Quality of Life, Aesthetic Result and Health Economy in Breast Reconstruction","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":220,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT07040540","title":"Hemodynamic Effects of Intradermal Methylene Blue During Breast Surgery Under General Anesthesia","phase":"","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital","has_results":false},{"nct_id":"NCT04688762","title":"The E-consult Application for Patients With Breast Cancer: Interest in Empathy and Empowerment of Patients.","phase":"","overall_status":"COMPLETED","enrollment_count":206,"lead_sponsor_name":"Centre Francois Baclesse","has_results":false},{"nct_id":"NCT03870919","title":"Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT06601868","title":"The Impact of Nutritional Optimization to Enhance Postoperative Outcomes Using the R-Support Supplements","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Universitair Ziekenhuis Brussel","has_results":false},{"nct_id":"NCT04059835","title":"OptiBra Study, Optimal Postoperative Bra After Breastcancer Surgery","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT03761940","title":"Health Status of Women With Breast Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT07321145","title":"A Retrospective Analysis of Robot-Assisted Versus Endoscopic Breast-Conserving Surgery for Breast Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT06592053","title":"Affecting Factors for Chronic Pain After Mastectomy","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Ankara Etlik City Hospital","has_results":false},{"nct_id":"NCT06773143","title":"Effect of Subanesthetic Dose of Esketamine on Sleep Quality","phase":"NA","overall_status":"RECRUITING","enrollment_count":184,"lead_sponsor_name":"Nanjing First Hospital, Nanjing Medical University","has_results":false},{"nct_id":"NCT07032220","title":"Application of Targeted Axillary Lymph Node Resection in Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: an Open-label, Multicenter Study","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":175,"lead_sponsor_name":"Fujian Medical University Union Hospital","has_results":false},{"nct_id":"NCT07352930","title":"A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":172,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT05797454","title":"Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":170,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT07029646","title":"Comparative Research on the Accuracy of Margin Interpretation in Breast-Conserving Surgery for Breast Cancer: Cell Microscopic Imaging and Standard Frozen Pathology","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":167,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT07131592","title":"Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03432429","title":"Real Time Tissue Characterisation Using Mass Spectrometry REI-EXCISE iKnife Study","phase":"","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT03494244","title":"Evaluation of ADM Soft Tissue Reinforcement","phase":"","overall_status":"UNKNOWN","enrollment_count":152,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06835426","title":"High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins","phase":"NA","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Algemeen Ziekenhuis Maria Middelares","has_results":false},{"nct_id":"NCT05560633","title":"Nipple-sparing Mastectomy in Combined With Buried Flap Monitoring","phase":"","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06427044","title":"Effect of Bupivacaine Liposome Anterior Serratus Deep Block on Chronic Pain After Breast Cancer Surgery: a Randomized Controlled Study","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":143,"lead_sponsor_name":"Lu Hua","has_results":false},{"nct_id":"NCT03651973","title":"Prevention of Sequelae Pain After Breast Cancer Surgery by Self-massages and Self Stretching. Impact of Learning Workshops.","phase":"NA","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"Center Eugene Marquis","has_results":false},{"nct_id":"NCT03307525","title":"Pain After Breast Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":141,"lead_sponsor_name":"Duke University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}